Please login to the form below

Not currently logged in
Email:
Password:

RVT-602

This page shows the latest RVT-602 news and features for those working in and with pharma, biotech and healthcare.

Takeda forms new women's health and cancer company

Takeda forms new women's health and cancer company

Myovant has also received an exclusive, commercial license for RVT-602, Takeda's oligopeptide kisspeptin receptor agonist for the treatment of female infertility.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....